BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Dec. 20, 2007
View Archived Issues
Idera Signs $421M Deal For TLR9 Cancer Agonists
The deal-making furor surrounding Toll-like receptors (TLRs) is continuing, with Merck KGaA agreeing to pay up to $421 million for worldwide rights in cancer indications to Idera Pharmaceuticals Inc.'s for TLR9 agonists. (BioWorld Today)
Read More
Galapagos Inks $395M Deal With Lilly For Osteo Drugs
Read More
Santaris Gets $700M From GSK In Antiviral LNA-Based Drug Pact
Read More
London Leukemia Case Linked To Gene Therapy
Read More
Alkermes Gets $166M Boost From GSK's Reliant Buyout
Read More
Other News To Note
Read More
Clinic Roundup
Read More
Financings Roundup
Read More
Appointments And Advancements
Read More